{"filing":{"accession_number":"0001213900-26-059526","cik":"0001139685","ticker":"AIDX","company_name":"20/20 Biolabs, Inc.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"ea0291642-8k_2020bio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026059526/ea0291642-8k_2020bio.htm"},"events":[{"id":9840,"run_id":8626,"accession_number":"0001213900-26-059526","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses a press release issued on May 20, 2026 regarding financial results for the quarter ended March 31, 2026, furnished under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure, which is material to investors as it provides periodic financial performance information.","company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":652,"accession_number":"0001213900-26-059526","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a press release issued on May 20, 2026 regarding financial results for the quarter ended March 31, 2026, furnished under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure, which is material to investors as it provides periodic financial performance information.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:50:31.520177+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":652,"accession_number":"0001213900-26-059526","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a press release issued on May 20, 2026 regarding financial results for the quarter ended March 31, 2026, furnished under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure, which is material to investors as it provides periodic financial performance information.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:50:31.520177+00:00","company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","filing_date":"2026-05-20"}]}